Compare EML & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EML | CHRS |
|---|---|---|
| Founded | 1858 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 130.2M | 186.0M |
| IPO Year | N/A | 2014 |
| Metric | EML | CHRS |
|---|---|---|
| Price | $20.18 | $1.36 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $4.51 |
| AVG Volume (30 Days) | 9.9K | ★ 1.0M |
| Earning Date | 11-04-2025 | 11-06-2025 |
| Dividend Yield | ★ 2.14% | N/A |
| EPS Growth | N/A | N/A |
| EPS | 1.19 | ★ 1.34 |
| Revenue | $258,121,226.00 | ★ $277,728,000.00 |
| Revenue This Year | $1.56 | N/A |
| Revenue Next Year | $7.00 | $67.29 |
| P/E Ratio | $19.91 | ★ $1.01 |
| Revenue Growth | N/A | ★ 152.07 |
| 52 Week Low | $18.49 | $0.71 |
| 52 Week High | $30.72 | $1.89 |
| Indicator | EML | CHRS |
|---|---|---|
| Relative Strength Index (RSI) | 52.19 | 51.56 |
| Support Level | $18.82 | $1.18 |
| Resistance Level | $20.86 | $1.35 |
| Average True Range (ATR) | 0.65 | 0.09 |
| MACD | 0.22 | 0.03 |
| Stochastic Oscillator | 67.85 | 67.35 |
The Eastern Co manages industrial businesses that design, manufacture, and sell engineered solutions to industrial markets. The company manages the financial, operational, and strategic performance of its businesses to increase cash generation, operating earnings, and long-term shareholder value. It operates in the United States and Other Countries and generates the majority of its revenue from the United States.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.